Skip to Content

Join the 'Alogliptin' group to help and get support from people like you.

Alogliptin News

Intensive Type 2 Diabetes Treatment Can Extend Survival: Study

Posted 8 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 7, 2016 – Intensive management of type 2 diabetes can make a difference in how long and how well you live, even if you don't start until middle age, researchers report. People who were already at risk of type 2 diabetes complications were randomly selected to continue with their normal treatment or to be placed in an aggressive and multipronged treatment group. Two decades after the study began, the researchers found that people in the aggressive treatment group lived almost eight years longer. Not only that, they lived better – their risk of heart disease, kidney disease and blindness all dropped. The only complication that didn't seem to improve was nerve damage caused by diabetes. "Early, intensified intervention in type 2 diabetes patients with microalbuminuria with both target-driven pharmacological (medication) and behavioral actions increased life span. And, ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Byetta, Janumet, Glyburide, Saxenda, Bydureon, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride

FDA Medwatch Alert: Diabetes Medications Containing Saxagliptin and Alogliptin: Drug Safety Communication - Risk of Heart Failure

Posted 5 Apr 2016 by Drugs.com

ISSUE: An FDA safety review has found that type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease. As a result, FDA is adding new warnings to the drug labels about this safety issue. Medicines containing saxagliptin and alogliptin include: Onglyza (saxagliptin) Kombiglyze XR (saxagliptin and metformin extended release) Nesina (alogliptin) Kazano (alogliptin and metformin) Oseni (alogliptin and pioglitazone) This Communication is an update to the 02/11/2014 FDA Drug Safety Communication. BACKGROUND: Saxagliptin and alogliptin are part of the class of dipeptidyl peptidase-4 (DPP-4) inhibitor drugs, which are used with diet and exercise to lower blood sugar in adults with type 2 diabetes. FDA evaluated two large clinical trials conducted in patients with heart disease. These ... Read more

Related support groups: Diabetes, Type 2, Onglyza, Nesina, Saxagliptin, Kombiglyze XR, Oseni, Alogliptin, Alogliptin/pioglitazone, Kazano, Metformin/saxagliptin, Alogliptin/metformin

FDA: 2 Diabetes Drugs May Be Linked to Heart Failure Risk

Posted 5 Apr 2016 by Drugs.com

TUESDAY, April 5, 2016 – Diabetes drugs containing saxagliptin and alogliptin may raise the risk of heart failure, particularly in patients with heart or kidney disease, U.S. health officials warned Tuesday. Drugs containing these ingredients are Onglyza (saxagliptin), Kombiglyze XR (saxagliptin and metformin extended release), Nesina (alogliptin), Kazano (alogliptin and metformin) and Oseni (alogliptin and pioglitazone), the U.S. Food and Drug Administration said. People with type 2 diabetes who use these drugs should not stop taking them without consulting with their doctor, the FDA said. The agency added that patients on these drugs should contact their doctor if they develop signs and symptoms of heart failure, including: Unusual shortness of breath during daily activities. Difficulty breathing when lying down. Tiredness, weakness or fatigue. Weight gain with swelling of the ... Read more

Related support groups: Diabetes, Type 2, Heart Failure, Congestive Heart Failure, Onglyza, Left Ventricular Dysfunction, Diabetes Mellitus, Alogliptin, Nesina, Saxagliptin, Kombiglyze XR, Oseni, Alogliptin/pioglitazone, Kazano, Alogliptin/metformin, Metformin/saxagliptin

Cost of Insulin Rises Threefold in Just a Decade: Study

Posted 5 Apr 2016 by Drugs.com

TUESDAY, April 5, 2016 – Americans with diabetes who rely on insulin to keep their blood sugar levels in check are facing sticker shock: A new study finds the price of insulin has tripled in only 10 years. Moreover, since 2010, per-person spending on insulin in the United States was more than spending on all other diabetes drugs, the study found. "The cost of insulin has risen rapidly over the last few years," said study senior author Philip Clarke, a professor of health economics at the University of Melbourne in Australia. Clarke added there should be an assessment to see whether this price hike is justifiable in terms of improved clinical outcomes. One reason for the price climb, he said, is a switch from human insulins to analog insulins, which cost more but may offer additional benefits. Also, doctors are more apt to prescribe insulin for people with type 2 diabetes now, Clarke ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Diabetes, Type 1, Januvia, Glucophage, Novolog, Diabetic Neuropathy, Glipizide, Humalog, Byetta, Insulin Resistance, Janumet, Diabetic Nerve Damage, Glyburide, Saxenda, Bydureon, Lantus Solostar

New Diabetes Cases Among Americans Drop for First Time in Decades: CDC

Posted 1 Dec 2015 by Drugs.com

TUESDAY, Dec. 1, 2015 – In a sign that Americans may finally be turning the corner in the fight against diabetes – and possibly obesity – federal health statistics released Tuesday show that the number of new cases of diabetes has dropped for the first time in decades. The decline wasn't sudden or dramatic. But, the number of new diabetes cases went from 1.7 million in 2009 to 1.4 million in 2014, according to the U.S. Centers for Disease Control and Prevention. "It seems pretty clear that incidence rates have now actually started to drop. Initially it was a little surprising because I had become so used to seeing increases everywhere we looked," CDC researcher Edward Gregg told The New York Times. The proportion of Americans with diabetes is still twice what it was in the early 1990s. And not every racial group has made strides against the blood sugar disease, which is often ... Read more

Related support groups: Diabetes, Type 2, Obesity, Metformin, Insulin, Weight Loss, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Byetta, Janumet, Glyburide, Saxenda, Bydureon, Lantus Solostar, Invokana, Levemir

Too Many Seniors With Diabetes Are Overtreated, Study Suggests

Posted 29 Oct 2015 by Drugs.com

THURSDAY, Oct. 29, 2015 – When it comes to treating seniors with diabetes, new research suggests that doctors often don't cut back on medications, even when treatment goals are surpassed. The study found that when people had potentially dangerous low blood sugar levels, just 27 percent had their medicines decreased. And when blood pressure treatments lowered blood pressure levels too much, just 19 percent saw a reduction in their medications. "As people get older, the risks of overtreating become greater, and the benefits become shorter. We have to start emphasizing that more isn't always better," said study author Dr. Jeremy Sussman, an assistant professor of internal medicine at the University of Michigan in Ann Arbor and a primary care doctor at the Ann Arbor VA System. The findings were published online Oct. 26 in the journal JAMA Internal Medicine. Practice guidelines generally ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Byetta, Janumet, Glyburide, Saxenda, Bydureon, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride

FDA Warns of Joint Pain Tied to Common Type 2 Diabetes Drugs

Posted 31 Aug 2015 by Drugs.com

FRIDAY, Aug. 28, 2015 – Use of a class of widely prescribed medications for type 2 diabetes is tied to severe joint pain in some patients, the U.S. Food and Drug Administration warned on Friday. The drugs – sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta) and alogliptin (Nesina) – come from a newer class of medications called DPP-4 inhibitors. The drugs can be taken alone or used in conjunction with other diabetes drugs, such as metformin. DPP-4 inhibitors help fight type 2 diabetes by boosting the amount of insulin the body produces after each meal, when blood sugar levels are typically high. However, in a statement, the FDA said the medications "may cause joint pain that can be severe and disabling," and the agency "has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class." The FDA stressed that patients who take ... Read more

Related support groups: Diabetes, Type 2, Metformin, Januvia, Glucophage, Janumet, Pre-Diabetes, Onglyza, Diabetes Mellitus, Tradjenta, Glucophage XR, ActoPlus Met, Sitagliptin, Glumetza, Janumet XR, Glyburide/Metformin, Jentadueto, Avandamet, Glyxambi, Glucovance, Metformin/Pioglitazone

FDA Medwatch Alert: DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain

Posted 28 Aug 2015 by Drugs.com

ISSUE: The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors. See the Drug Safety Communication for a complete list of all FDA-approved DPP-4 inhibitors. BACKGROUND: DPP-4 inhibitors are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. When untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease. These medicines are available as single-ingredient products and in combination with other diabetes medicines such as metformin. RECOMMENDATION: Patients should not stop taking their DPP-4 ... Read more

Related support groups: Diabetes, Type 2, Januvia, Janumet, Onglyza, Tradjenta, Sitagliptin, Janumet XR, Jentadueto, Glyxambi, Linagliptin, Oseni, Saxagliptin, Kombiglyze XR, Alogliptin, Nesina, Kazano, Metformin/Sitagliptin, Alogliptin/pioglitazone, Simvastatin/sitagliptin, Linagliptin/metformin

Health Tip: Diabetes Can Take a Toll on Teeth and Mouth

Posted 10 Aug 2015 by Drugs.com

-- Diabetes, especially when uncontrolled, can cause damage to your mouth and teeth. The Mouthhealthy.org website says possible effects of diabetes on the teeth and mouth include: Dry mouth, due to decreased saliva production. Increased risk of cavities due to less saliva. Gingivitis, characterized by bleeding, inflamed gums. Difficulty tasting food. Slower healing of mouth wounds. Increased risk of infection. Among diabetic children. teeth emerging earlier than expected. Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Xerostomia, Victoza, Oral and Dental Conditions, Lantus, Toothache, Diabetes, Type 1, Januvia, Glucophage, Novolog, Burning Mouth Syndrome, Diabetic Neuropathy, Glipizide, Humalog, Byetta, Insulin Resistance, Janumet, Diabetic Nerve Damage

People With Type 2 Diabetes Do Benefit From Blood Sugar Checks

Posted 5 Aug 2015 by Drugs.com

WEDNESDAY, Aug. 5, 2015 – Personalized blood sugar self-monitoring benefits people with type 2 diabetes even if they're not taking insulin, a new small study shows. Some experts have questioned the value of self-monitoring in this group, and many insurers – including Medicare – limit the reimbursement of blood sugar (glucose) testing strips to one a day for people with type 2 diabetes. This study included 11 people with type 2 diabetes who worked with the researchers to create personalized, structured self-monitoring blood glucose schedules. In most cases, self-monitoring twice a day was the most helpful in providing meaningful information about blood sugar levels. However, there was room for individualization based on a patient's type of lifestyle and needs. For example, a patient might check their blood sugar twice a day three days a week instead of once a day seven days a week, ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Byetta, Janumet, Glyburide, Saxenda, Bydureon, Lantus Solostar, Invokana, Levemir, Actos, Pre-Diabetes

FDA Medwatch Alert: Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas

Posted 14 Mar 2013 by Drugs.com

ISSUE: FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics. These findings were based on examination of a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes. FDA has asked the researchers to provide the methodology used to collect and study these specimens and to provide the tissue samples so the Agency can further investigate potential pancreatic toxicity associated with the incretin mimetics. BACKGROUND: Drugs in the incretin mimetic class include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin ... Read more

Related support groups: Diabetes, Type 2, Victoza, Januvia, Janumet, Byetta, Bydureon, Liraglutide, Tradjenta, Sitagliptin, Jentadueto, Linagliptin, Exenatide, Oseni, Alogliptin, Nesina, Alogliptin/pioglitazone, Kazano, Metformin/Sitagliptin, Juvisync, Alogliptin/metformin

Ask a Question

Further Information

Related Condition Support Groups

Diabetes, Type 2

Related Drug Support Groups

Nesina

Alogliptin Patient Information at Drugs.com